secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001411690-25-000045
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano Q1 revenue $6.5M, down 26% YoY; FY2025 guidance $26-30M
---------------------------------------------------------------

- Q1 revenue $6.5M vs $8.8M YoY, down 26%; GAAP gross margin improved to 46% from 32%.
- Flowcell sales 6,994 units (-15% YoY); to routine customers up 1% after adjusting for new adds.
- GAAP operating expense $11.4M, down 66% YoY from cost cuts and restructuring.
- Cash, equivalents and investments $29.2M; cash runway extended into Q1 2026.
- FY2025 revenue guidance updated to $26-30M; Q2 revenue expected $6.3-6.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000141169025000045/0001411690-25-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000141169025000045/bngo-20250514.htm
  HTML page:      https://secwatch.observer/filing/0001411690-25-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer